Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference
February 09 2023 - 4:01PM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced that
members of the Aclaris management team will participate in a
fireside chat during the Virtual SVB Securities Global Biopharma
Conference on Tuesday, February 14, 2023 at 9:20 AM ET.
A webcast of the fireside chat may be accessed through the
“Events” page of the “Investors” section of Aclaris’ website,
www.aclaristx.com. The webcast will be archived for at least 30
days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Aclaris Therapeutics Contact:
Robert A. Doody Jr.Vice President, Investor
Relations484-639-7235rdoody@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2023 to Apr 2024